According to copy-number analysis, syndecan-4 was highly amplified in rhabdomyosarcoma, especially in FNRMSs, as genomic analyses revealed copy-number amplification events in 28% of fusion-negative tumors (Fig. 8b). Here, SDC4 is linked to rhabdomyosarcoma.